Condition
Stage IIIA Intraocular Melanoma
Total Trials
3
Recruiting
0
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results50% success
Data Visualizations
Phase Distribution
3Total
P 2 (3)
Trial Status
Completed1
Terminated1
Active Not Recruiting1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT02068586Phase 2Active Not Recruiting
Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma
NCT01533948Phase 2Terminated
Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery
NCT00085189Phase 2Completed
Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma
Showing all 3 trials